Compare · AVR vs STE
AVR vs STE
Side-by-side comparison of Anteris Technologies Global Corp. (AVR) and STERIS plc (Ireland) (STE): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both AVR and STE operate in Industrial Specialties (Health Care), so they compete in similar markets.
- STE is the larger of the two at $21.03B, about 34.0x AVR ($618.4M).
- Over the past year, AVR is up 56.7% and STE is down 4.3% - AVR leads by 61.0 points.
- AVR has been more active in the news (5 items in the past 4 weeks vs 1 for STE).
- STE has more recent analyst coverage (16 ratings vs 6 for AVR).
- Company
- Anteris Technologies Global Corp.
- STERIS plc (Ireland)
- Price
- $6.36+3.33%
- $214.46-1.11%
- Market cap
- $618.4M
- $21.03B
- 1M return
- +19.55%
- -2.52%
- 1Y return
- +56.65%
- -4.31%
- Industry
- Industrial Specialties
- Industrial Specialties
- Exchange
- NASDAQ
- NYSE
- IPO
- 2024
- News (4w)
- 5
- 1
- Recent ratings
- 6
- 16
STERIS plc (Ireland)
STERIS plc provides infection prevention and other procedural products and services worldwide. It operates in three segments: Healthcare, Applied Sterilization Technologies, and Life Sciences. The Healthcare segment offers cleaning chemistries and sterility assurance products; accessories for gastrointestinal (GI) procedures, washers, sterilizers, and other pieces of capital equipment for the operation of a sterile processing department; and equipment used directly in the operating room, including surgical tables, lights, and connectivity solutions, as well as equipment management services. It also provides capital equipment installation, maintenance, upgradation, repair, and troubleshooting services; preventive maintenance programs and repair services; instrument and endoscope repair and maintenance services; and custom process improvement consulting and outsourced instrument sterile processing services. This segment offers its products and services to acute care hospitals and other healthcare settings. The Applied Sterilization Technologies segment provides contract sterilization and testing services for medical device and pharmaceutical manufacturers through a network of approximately 50 contract sterilization and laboratory facilities. The Life Sciences segment designs, manufactures and sells consumable products, such as formulated cleaning chemistries, barrier and sterility assurance products, steam and vaporized hydrogen peroxide sterilizers, and washer disinfectors. This segment also offers equipment installation, maintenance, upgradation, repair, and troubleshooting services; and preventive maintenance programs and repair services. The company is based in Dublin, Ireland.
Latest AVR
- SEC Form 424B3 filed by Anteris Technologies Global Corp.
- Anteris Technologies Global Corp. filed SEC Form 8-K: Termination of a Material Definitive Agreement
- Anteris Technologies Secures CMS Reimbursement Supporting U.S. Site Activation for PARADIGM Trial
- SEC Form 424B3 filed by Anteris Technologies Global Corp.
- Anteris Technologies Global Corp. filed SEC Form 8-K: Entry into a Material Definitive Agreement
- SEC Form 424B3 filed by Anteris Technologies Global Corp.
- SEC Form EFFECT filed by Anteris Technologies Global Corp.
- Cantor Fitzgerald resumed coverage on Anteris Technologies Global Corp. with a new price target
- Wells Fargo initiated coverage on Anteris Technologies Global Corp. with a new price target
- SEC Form POS AM filed by Anteris Technologies Global Corp.
Latest STE
- STERIS to Host a Conference Call for Fiscal 2026 Fourth Quarter and Full Year Results on May 12, 2026
- Teleflex Announces Governance Updates
- SEC Form 8-K filed by STERIS plc (Ireland)
- Amendment: SEC Form SCHEDULE 13G/A filed by STERIS plc (Ireland)
- Director Feldmann Cynthia L exercised 3,098 units of Ordinary Shares at a strike of $152.32 and sold $734,877 worth of Ordinary Shares (3,098 units at $237.21) (SEC Form 4)
- SEC Form 144 filed by STERIS plc (Ireland)
- SEC Form 10-Q filed by STERIS plc (Ireland)
- STERIS plc (Ireland) filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
- STERIS Announces Financial Results for Fiscal 2026 Third Quarter
- STERIS Announces Dividend of $0.63 per share